These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 35942815)

  • 1. Considerations for routinely testing for high lipoprotein(a).
    Nurmohamed NS; Moriarty PM; Stroes ES
    Curr Opin Lipidol; 2023 Aug; 34(4):174-179. PubMed ID: 35942815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Considerations for routinely testing for high Lp(a).
    Nurmohamed NS; Moriarty PM; Stroes ESG
    Curr Opin Lipidol; 2022 Jun; 33(3):213-218. PubMed ID: 35695619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2/3.
    Malick WA; Goonewardena SN; Koenig W; Rosenson RS
    J Am Coll Cardiol; 2023 Apr; 81(16):1633-1645. PubMed ID: 37076218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies.
    Chan DC; Watts GF
    Clin Ther; 2023 Nov; 45(11):1034-1046. PubMed ID: 37524569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies.
    Alhomoud IS; Talasaz A; Mehta A; Kelly MS; Sisson EM; Bucheit JD; Brown R; Dixon DL
    Pharmacotherapy; 2023 Oct; 43(10):1051-1063. PubMed ID: 37464942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives.
    Wu MF; Xu KZ; Guo YG; Yu J; Wu Y; Lin LM
    Cardiovasc Drugs Ther; 2019 Dec; 33(6):739-748. PubMed ID: 31655942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lp(a): a New Pathway to Target?
    Nurmohamed NS; Kraaijenhof JM; Stroes ESG
    Curr Atheroscler Rep; 2022 Nov; 24(11):831-838. PubMed ID: 36066785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
    Vuorio A; Watts GF; Schneider WJ; Tsimikas S; Kovanen PT
    J Intern Med; 2020 Jan; 287(1):2-18. PubMed ID: 31858669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review.
    Duarte Lau F; Giugliano RP
    JAMA Cardiol; 2022 Jul; 7(7):760-769. PubMed ID: 35583875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease.
    Tada H; Takamura M; Kawashiri MA
    J Atheroscler Thromb; 2019 Jul; 26(7):583-591. PubMed ID: 31061262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?
    Reiner Ž
    Curr Atheroscler Rep; 2019 Mar; 21(4):14. PubMed ID: 30847681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein(a): cardiovascular risk and emerging therapies.
    Fujino M; Nicholls SJ
    Expert Rev Cardiovasc Ther; 2023 Apr; 21(4):259-268. PubMed ID: 37010028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lp(a) in the Pathogenesis of Aortic Stenosis and Approach to Therapy with Antisense Oligonucleotides or Short Interfering RNA.
    Di Costanzo A; Indolfi C; Franzone A; Esposito G; Spaccarotella CAM
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consensus document on Lipoprotein(a) from the Italian Society for the Study of Atherosclerosis (SISA).
    Chiesa G; Zenti MG; Baragetti A; Barbagallo CM; Borghi C; Colivicchi F; Maggioni AP; Noto D; Pirro M; Rivellese AA; Sampietro T; Sbrana F; Arca M; Averna M; Catapano AL
    Nutr Metab Cardiovasc Dis; 2023 Oct; 33(10):1866-1877. PubMed ID: 37586921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein(a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and/or Residual Risk.
    Melita H; Manolis AA; Manolis TA; Manolis AS
    J Cardiovasc Pharmacol; 2022 Jan; 79(1):e18-e35. PubMed ID: 34694242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.
    O'Donoghue ML; Rosenson RS; Gencer B; López JAG; Lepor NE; Baum SJ; Stout E; Gaudet D; Knusel B; Kuder JF; Ran X; Murphy SA; Wang H; Wu Y; Kassahun H; Sabatine MS;
    N Engl J Med; 2022 Nov; 387(20):1855-1864. PubMed ID: 36342163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Antisense Therapies Targeting Lipoprotein(a).
    Plakogiannis R; Sorbera M; Fischetti B; Chen M
    J Cardiovasc Pharmacol; 2021 Jul; 78(1):e5-e11. PubMed ID: 34232223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a).
    Vuorio A; Watts GF; Kovanen PT
    Eur Heart J; 2017 Dec; 38(48):3555-3559. PubMed ID: 29029165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent updates on therapeutic targeting of lipoprotein(a) with RNA interference.
    Sekhar A; Kuttan A; Lange RA
    Curr Opin Cardiol; 2024 Jul; 39(4):292-299. PubMed ID: 38547148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
    Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
    Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.